Vaccination against Alzheimer disease: An update on future strategies

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 4, 2014, Pages 847-851

  Fettelschoss, Antonia ^a,b   Zabel, Franziska ^a,b   Bachmann, Martin F ^b,c  

^a Saiba GmbH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Abeta; Alzheimer; Antibody; Third generation; Vaccine

Indexed keywords

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; BAPINEUZUMAB; BETA SECRETASE; CAD 106; CORTICOSTEROID; DIPHTHERIA TOXOID CRM197; GAMMA SECRETASE; IMMUNOGLOBULIN G ANTIBODY; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PLACEBO; QS 21; SOLANEZUMAB; TAU PROTEIN; UNCLASSIFIED DRUG; VANUTIDE CRIDIFICAR;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MENINGOENCEPHALITIS; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN AGGREGATION; PROTEIN CEREBROSPINAL FLUID LEVEL; REVIEW; VASOGENIC EDEMA; ANIMAL; DISEASE MODEL; DRUG DEVELOPMENT; IMMUNOLOGY; PROCEDURES; TRANSGENIC MOUSE; TREATMENT OUTCOME; TRENDS; VACCINATION;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; ANIMALS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HUMANS; MICE, TRANSGENIC; TREATMENT OUTCOME; VACCINATION;

EID: 84899860967     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.28183     Document Type: Review

References (35)

1. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007; 3:186-91; PMID:19595937; http://dx.doi.org/10.1016/j.jalz.2007.04.381
2. Corrada MM, Brookmeyer R, Paganini-Hill A, Berlau D, Kawas CH. Dementia incidence continues to increase with age in the oldest old: the 90+ study. Ann Neurol 2010; 67:114-21; PMID:20186856; http://dx.doi.org/10.1002/ana.21915
3. Wimo A, Winblad B, Jönsson L. The worldwide societal costs of dementia: Estimates for 2009. Alzheimers Dement 2010; 6:98-103; PMID:20298969; http://dx.doi.org/10.1016/j.jalz.2010.01.010
4. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer's disease: clinical trials and drug development. Lancet Neurol 2010; 9:702-16; PMID:20610346; http://dx.doi.org/10.1016/S1474-4422(10)70119-8
5. Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 2010; 6:108-19; PMID:20140000; http://dx.doi.org/10.1038/nrneurol.2009.219
6. Goedert M, Wischik CM, Crowther RA, Walker JE, Klug A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci U S A 1988; 85:4051-5; PMID:3131773; http://dx.doi.org/10. 1073/pnas.85.11.4051
7. Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, Hyman B, Burton MA, Goldstein LE, Duong S, Tanzi RE, et al. The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One 2010; 5:e9505; PMID:20209079; http://dx.doi.org/10.1371/journal.pone.0009505
8. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature 2004; 430:631-9; PMID:15295589; http://dx.doi.org/10.1038/nature02621
9. Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 2013; 9:106-18; PMID:23296339; http://dx.doi.org/10.1038/nrneurol.2012.263
10. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400:173-7; PMID:10408445; http://dx.doi.org/10.1038/22124
11. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000; 408:982-5; PMID:11140686; http://dx.doi.org/10.1038/35050116
12. Röskam S, Neff F, Schwarting R, Bacher M, Dodel R. APP transgenic mice: the effect of active and passive immunotherapy in cognitive tasks. Neurosci Biobehav Rev 2010; 34:487-99; PMID:19857518; http://dx.doi.org/10.1016/ j.neubiorev.2009.10.006
13. Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, Millais SB, Donoghue S. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 2005; 64:94-101; PMID:15642910; http://dx.doi.org/10.1212/01.WNL.0000148604.77591.67
14. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003; 61:46-54; PMID:12847155; http://dx.doi.org/10.1212/01.WNL.0000073623.84147.A8
15. Hock C, Konietzko U, Papassotiropoulos A, Wollmer A, Streffer J, von Rotz RC, Davey G, Moritz E, Nitsch RM. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat Med 2002; 8:1270-5; PMID:12379846; http://dx.doi.org/10.1038/nm783
16. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Müller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003; 38:547-54; PMID:12765607; http://dx.doi.org/10.1016/S0896-6273(03)00294-0
17. Ferrer I, Boada Rovira M, Sánchez Guerra ML, Rey MJ, Costa-Jussá F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 2004; 14:11-20; PMID:14997933; http://dx.doi.org/10.1111/j.1750-3639.2004.tb00493.x
18. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, et al.; AN1792(QS-21)-201 Study Team. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64:1553-62; PMID:15883316; http://dx.doi.org/10.1212/01. WNL.0000159740.16984.3C
19. Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, Seubert P, Games D, Kirby L, Schenk D. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005; 64:129-31; PMID:15642916; http://dx.doi.org/10.1212/01.WNL.0000148590.39911.DF
20. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003; 9:448-52; PMID:12640446; http://dx.doi.org/10.1038/nm840
21. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M; AN1792(QS-21)-201 Study. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005; 64:1563-72; PMID:15883317; http://dx.doi.org/10.1212/01.WNL.0000159743.08996.99
22. Vellas B, Black R, Thal LJ, Fox NC, Daniels M, McLennan G, Tompkins C, Leibman C, Pomfret M, Grundman M; AN1792 (QS-21)-251 Study Team. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res 2009; 6:144-51; PMID:19355849; http://dx.doi.org/10.2174/156720509787602852
23. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008; 372:216-23; PMID:18640458; http://dx.doi.org/10.1016/S0140- 6736(08)61075-2
24. Wiessner C, Wiederhold KH, Tissot AC, Frey P, Danner S, Jacobson LH, Jennings GT, Lüönd R, Ortmann R, Reichwald J, et al. The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci 2011; 31:9323-31; PMID:21697382; http://dx.doi.org/10.1523/JNEUROSCI. 0293-11.2011
25. Graf A, et al. Optimization of the treatment regimen with active Aβ immunotherapy CAD106 in alzheimer patients. Alzheimers Dement 2010; 6:S532; http://dx.doi.org/10.1016/j.jalz.2010.05.1775
26. Winblad B. S2-04-06: Safety, tolerability and immunogenicity of the Aβ immunotherapeutic vaccine CAD106 in a first-in-man study in Alzheimer patients. Alzheimers Dement 2008; 4:T128; http://dx.doi.org/10.1016/j.jalz.2008. 05.295
27. Winblad BG, et al. Results of the first-in-man study with the active Aβ Immunotherapy CAD106 in Alzheimer patients. Alzheimers Dement 2009; 5:113-P114; http://dx.doi.org/10.1016/j.jalz.2009.05.356
28. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010; 9:363-72; PMID:20189881; http://dx.doi.org/10.1016/S1474- 4422(10)70043-0
29. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, et al.; Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012; 367:795-804; PMID:22784036; http://dx.doi.org/10.1056/ NEJMoa1202753
30. Fletcher LC, Burke KE, Caine PL, Rinne NL, Braniff CA, Davis HR, Miles KA, Packer C. Diagnosing Alzheimer's disease: are we any nearer to useful biomarker-based, non-invasive tests? GMS Health Technol Assess 2013; 9:Doc01; PMID:23755087
31. Belluti F, Rampa A, Gobbi S, Bisi A. Small-molecule inhibitors/modulators of amyloid-β peptide aggregation and toxicity for the treatment of Alzheimer's disease: a patent review (2010-2012). Expert Opin Ther Pat 2013; 23:581-96; PMID:23425062; http://dx.doi.org/10.1517/13543776.2013.772983
32. Himmelstein DS, Ward SM, Lancia JK, Patterson KR, Binder LI. Tau as a therapeutic target in neurodegenerative disease. Pharmacol Ther 2012; 136:8-22; PMID:22790092; http://dx.doi.org/10.1016/j.pharmthera.2012.07.001
33. Tobinick E. Tumour necrosis factor modulation for treatment of Alzheimer's disease: rationale and current evidence. CNS Drugs 2009; 23:713-25; PMID:19689163; http://dx.doi.org/10.2165/11310810-000000000-00000
34. Boutajangout A, Sigurdsson EM, Krishnamurthy PK. Tau as a therapeutic target for Alzheimer's disease. Curr Alzheimer Res 2011; 8:666-77; PMID:21679154; http://dx.doi.org/10.2174/156720511796717195
35. www.clinicaltrials.gov